NewLimit
CA - South SFBiotechnology
Focus: NewLimit is a biotechnology company focused on epigenetic reprogramming therapies, headquartered in South San Francisco. The company targets rare diseases using proprietary epigenetic editing technology.
Profile data last refreshed 3h ago · AI intelligence enriched 2w ago
Open Jobs
12
Should You Work at NewLimit?
AI assessmentHigh-risk, high-reward opportunity suitable for scientists seeking deep technical ownership in emerging epigenetic space, but visibility into funding and timelines is critically limited.
Why Work Here
- Cutting-edge technology platform in epigenetic reprogramming with significant unmet need in rare diseases
- Diverse hiring across 9 specialized departments (Immunology, Predictive Modeling, Single Cell Technology, Epigenetic Editing) signals multi-modal scientific ambition
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for NewLimit
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.